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Antibody genes are first rearranged by V(D)J   
recombination  during  B  lymphocyte  develop-
ment and then further diversified in the periph-
ery after encountering cognate antigen. The latter 
is achieved by the mechanism of somatic hyper-
mutation (SHM), which introduces random mu-
tations over the exon that encodes the antibody 
variable region. Coupled to phenotypic selection 
during the germinal center reaction, SHM results 
in the overall maturation of the antibody response. 
SHM is initiated by activation-induced deami-
nase (AID), which deaminates dC to dU in the Ig 
loci. Processing of the dU by specific DNA repair 
enzymes  produces  the  full  spectrum  of  SHM   
(Di Noia and Neuberger, 2007; Peled et al., 2008). 
In addition, AID also targets the DNA immedi-
ately preceding the constant exons that encode for 
the different antibody isotypes in the heavy chain 
locus. Processing of the dU in these switch regions 
leads to the DNA breaks necessary for class switch 
recombination (CSR; Stavnezer et al., 2008).
AID being a mutator enzyme sufficient to 
cause  cancer  in  transgenic  models  (Okazaki   
et al., 2003; Pasqualucci et al., 2008), there has 
been a well-deserved emphasis in studying its 
regulation.  Gene  expression  regulation  is  an 
important step during normal B cell develop-
ment, with AID being mostly restricted to ger-
minal center B cells (Muramatsu et al., 1999; 
Crouch et al., 2007). However, AID can nor-
mally be expressed outside of the B cell com-
partment, the exact physiological relevance of 
which is still unclear, although it may influence 
the expression of many genes by affecting DNA 
methylation  (Morgan  et  al.,  2004;  Macduff   
et al., 2009; Pauklin et al., 2009; Bhutani et al., 
2010; Popp et al., 2010). Importantly, there is 
CORRESPONDENCE  
Javier M. Di Noia: 
javier.di.noia@ircm.qc.ca
Abbreviations used: 17-AAG,  
17-allylamino-17- 
demethoxygeldanamycin; AID, 
activation-induced deaminase; 
CHIP, C terminus of Hsc70-
interacting protein; CHX,  
cycloheximide; CML, chronic 
myeloid leukemia; CSR, class 
switch recombination; EGFP, 
enhanced GFP; GA, geldana-
mycin; HRP, horseradish per-
oxidase; LMB, leptomycin B; 
MFI, mean fluorescence inten-
sity; PKA, protein kinase A; 
SHM, somatic hypermutation.
Regulation of activation-induced deaminase 
stability and antibody gene diversification  
by Hsp90
Alexandre Orthwein,1,2 Anne-Marie Patenaude,1 El Bachir Affar,4  
Alain Lamarre,5 Jason C. Young,6 and Javier M. Di Noia1,2,3,7
1Institut de Recherches Cliniques de Montréal, Montréal, Québec H2W 1R7, Canada
2Department of Microbiology and Immunology and 3Department of Medicine, Faculty of Medicine, University of Montréal, 
Montréal, Québec H3C 3J7, Canada
4Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal, Québec H1T 2M4, Canada
5Institut National de la Recherche Scientifique–Institut Armand-Frappier, Laval, Québec H7V 1B7, Canada
6Department of Biochemistry and 7Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, 
Québec H3A 1A3, Canada
Activation-induced deaminase (AID) is the mutator enzyme that initiates somatic hyper-
mutation and isotype switching of the antibody genes in B lymphocytes. Undesired byproducts 
of AID function are oncogenic mutations. AID expression levels seem to correlate with the 
extent of its physiological and pathological functions. In this study, we identify AID as  
a novel Hsp90 (heat shock protein 90 kD) client. We find that cytoplasmic AID is in  
a dynamic equilibrium regulated by Hsp90. Hsp90 stabilizes cytoplasmic AID, as specific 
Hsp90 inhibition leads to cytoplasmic polyubiquitination and proteasomal degradation of 
AID. Consequently, Hsp90 inhibition results in a proportional reduction in antibody gene 
diversification and off-target mutation. This evolutionarily conserved regulatory mechanism 
determines the functional steady-state levels of AID in normal B cells and B cell lymphoma 
lines. Thus, Hsp90 assists AID-mediated antibody diversification by stabilizing AID. Hsp90 
inhibition provides the first pharmacological means to down-regulate AID expression and 
activity, which could be relevant for therapy of some lymphomas and leukemias.
©  2010  Orthwein  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six   
months after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Multiple mechanisms seem to contribute to restrain AID 
protein. Subcellular localization is an important step in regu-
lating AID that also impinges on its stability because AID has 
a significantly shorter half-life in the nucleus than in the cyto-
plasm (Aoufouchi et al., 2008). In steady-state, the bulk of 
AID is cytoplasmic as a result of the integration of three 
mechanisms: nuclear import (Patenaude et al., 2009), nuclear 
export (Ito et al., 2004; McBride et al., 2004), and cytoplasmic 
retention (Patenaude et al., 2009). However, it is unknown 
whether AID stability is regulated in the cytoplasm. Several 
studies, including the analysis of AID-haploinsufficient mice 
(Sernández et al., 2008; Takizawa et al., 2008) or mice with 
altered AID levels resulting from manipulating microRNA 
regulation (de Yébenes et al., 2008; Dorsett et al., 2008; Teng 
et al., 2008) or enforcing transgenic overexpression (Robbiani 
et al., 2009), have suggested that AID protein levels are limit-
ing for and correlate with the efficiency of antibody diversifi-
cation  but  also  B  cell  lymphomagenesis. Therefore,  any 
mechanism impinging on the overall AID steady-state levels 
is important for balancing an efficient humoral immune re-
sponse with the associated risk of B cell transformation.
ample evidence that AID is expressed in a variety of human 
lymphomas (Greeve et al., 2003; Pasqualucci et al., 2004) and 
leukemias  (Albesiano  et  al.,  2003;  Feldhahn  et  al.,  2007;   
Klemm et al., 2009; Palacios et al., 2010). In fact, AID plays 
a  role  in  malignant  transformation  by  initiating  DNA   
double-strand breaks at various non-Ig loci, most prominently 
c-Myc, which in murine experimental plasmacytoma, and 
therefore most likely also in human Burkitt’s lymphoma, 
leads to the hallmark oncogenic c-Myc–IgH chromosomal 
translocation  (Ramiro  et  al.,  2004,  2006;  Robbiani  et  al., 
2008, 2009). A role for AID in the etiology of diffuse large   
B cell lymphoma is also very likely (Pasqualucci et al., 2001, 
2004, 2008). In chronic myeloid leukemia (CML), AID mu-
tates the BCR-ABL1 oncogene, leading to resistance to 
imatinib, the main therapeutic drug (Klemm et al., 2009). 
Moreover, AID expression in nonlymphoid tumors has also 
been shown (Endo et al., 2008). Therefore, it is important to 
understand AID posttranslational regulation, which may dif-
fer between normal and transformed cells and have important 
and varied implications in the several cell types that can   
express AID.
Figure 1.  AID interacts with Hsp90.  
(A) Ramos B cells stably expressing AID-Flag/HA 
were subjected to consecutive immuno-
precipitation with anti-Flag and anti-HA. 
Precipitated material was eluted with the 
specific peptides and separated by SDS-PAGE. 
Proteins were identified by mass spectrometry 
of tryptic peptides. The proteins relevant to 
this work are indicated next to the bands 
from where they were identified. One of two 
independent experiments is shown. MMM, 
molecular mass marker. (B) GFP and AID-GFP 
were immunoprecipitated from extracts of 
stably expressing Ramos cells and analyzed by 
Western blot (WB) to detect coimmuno-
precipitated endogenous Hsp90. One of three 
independent experiments is shown. (C) APO-
BEC2 (A2)-GFP and AID-GFP were immuno-
precipitated with anti-GFP from transiently 
expressing HEK293T cells cotransfected with 
Flag–Hsp90- and/or Myc–Hsp90-. Immuno-
precipitates (IP) were probed with anti-Flag 
and anti-Myc in Western blots. The filters 
were then probed with anti-Hsp90, which 
recognizes both isoforms, to verify that the 
overall Hsp90 level was similar after transfec-
tion. Anti-GFP confirmed similar immuno-
precipitation of the bait. One of two independent   
experiments is shown. (D) Lysates from 
HEK293T cells cotransfected with Myc–Hsp90- and Flag-tagged versions of AID or the indicated APOBECs or vector alone (V) were immunoprecipitated 
using anti-Flag and analyzed by Western blot with anti-Myc to verify the presence of Hsp90- and anti-Flag to confirm the immunoprecipitation of the 
baits. One of four independent experiments is shown. (E) Lysates from HEK293T cells cotransfected with Myc–Hsp90- and either vector only (V) or Flag-
tagged AID, A2, or AID-A2 chimeras (#1–5, described below in schematic form) were immunoprecipitated with anti-Flag. Immunoprecipitates were ana-
lyzed by Western blot using anti-Myc and anti-Flag antibodies. One of three independent experiments is shown. In schematics, horizontal green lines 
between dashed lines identify the fragments of AID replaced by the homologous region of A2 in each construct. Based on experimental A2 (Prochnow  
et al., 2007) and predicted AID (Patenaude et al., 2009) secondary structures, blue rectangles indicate  helixes, and red arrows indicate  sheets. Where 
indicated, aliquots (5%) of the whole cell lysates were probed to control for expression.JEM VOL. 207, November 22, 2010 
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Both isoforms are constitutively expressed in the B cell lines 
we used, although Hsp90- is the predominant form in rest-
ing primary mouse B cells, with Hsp90- increasing after cyto-
kine activation (Fig. S1, B and C). These results are in keeping 
with various studies indicating that mitogenic and cytokine 
stimuli up-regulate Hsp90-, whereas Hsp90- is constitu-
tively  expressed  (Hansen  et  al.,  1991;  Metz  et  al.,  1996; 
Csermely et al., 1998; Sreedhar et al., 2004). Hsp90- and 
Hsp90- share 90% similarity, and although they may have 
some nonoverlapping roles, for most functions, they are largely 
equivalent (Csermely et al., 1998; Sreedhar et al., 2004).
We then characterized the interaction between Hsp90 
and AID. Notably, the AID paralogue proteins APOBEC1, 
APOBEC2 (A2), and APOBEC3G, which share 50–60% 
similarity with AID (Conticello et al., 2005), did not co-
immunoprecipitate with Myc–Hsp90- (Fig. 1 D). This is con-
sistent with a recent study showing that zebra fish A2 interacts 
with the chaperone Unc45b but not with Hsp90- (Etard et al., 
2010). The region of AID interacting with Hsp90- could be 
mapped to the N-terminal half of the molecule by using 
AID-A2 chimeric proteins (Fig. 1 E). An AID mutant show-
ing impaired oligomerization (Patenaude et al., 2009) was still 
recognized by Hsp90 (Fig. S1 D). Phosphorylation can mod-
ulate client binding to Hsp90 (Dickey et al., 2007), but the 
known protein kinase A (PKA) sites within the N-terminal re-
gion of AID, Thr27, and Ser38, were not essential for the inter-
action (Fig. S1 D). These results suggest that Hsp90 specifically 
binds to AID by its N-terminal region in an oligomerization- 
and phosphorylation-independent fashion.
Hsp90 maintains the steady-state level of AID
The chaperone activity of Hsp90 depends on an ATP hydro-
lysis cycle, which is inhibited by geldanamycin (GA) and its 
derivatives,  like  17-allylamino-17-demethoxygeldanamycin 
We report the physical and functional interaction of AID 
with the Hsp90 (heat shock protein 90 kD) molecular chap-
erone pathway. Hsp90 is thought to be more selective of its 
range of substrates than other chaperones, playing a promi-
nent role in the structural stabilization and functional modu-
lation of many of its client proteins, rather than in their initial 
folding (Pratt and Toft, 2003; Whitesell and Lindquist, 2005; 
Pearl and Prodromou, 2006; Picard, 2006; Wandinger et al., 
2008). Indeed, the interaction with Hsp90 prevents protea-
somal degradation of AID in the cytoplasm, thereby deter-
mining the steady-state levels of functional AID.
RESULTS
AID specifically interacts with Hsp90
Immunopurification of AID-Flag/HA from cell extracts of 
Ramos B cells produced a complex but reproducible pattern 
of copurifying proteins (Fig. 1 A). Of note, we used a stable 
cell line expressing only 2.5-fold the amount of endogenous 
AID (Fig. S1 A). After identification of the associated proteins 
by  mass  spectrometry,  we  noticed  the  presence  of  several 
members of the Hsp90 molecular chaperone pathway (Whitesell 
and Lindquist, 2005), including the two major isoforms of 
Hsp90 ( and ), the Hsp90 cochaperone AHA-1, Hsp70/
Hsc70, and one Hsp40 cochaperone (DnaJa1), as well as sev-
eral proteasome subunits (Table I). The Hsp90, Hsp70, and 
Hsp40 proteins are known to cooperate in a multichaperone 
system (Picard, 2006; Wandinger et al., 2008). Given the im-
portance of Hsp90 in regulating the function of many signal 
transduction  and  nucleocytoplasmic  shuttling  proteins,  we 
decided to further explore this interaction. We confirmed the 
binding of AID to endogenous Hsp90 by coimmunoprecipi-
tation of AID-GFP from stably expressing Ramos cells (Fig. 1 B). 
We also confirmed that AID coimmunoprecipitated similarly 
with tagged versions of Hsp90- and Hsp90- (Fig. 1 C). 
Table I.  Proteins copurifying with AID-Flag-HA from Ramos B cells identified by mass spectrometry
HUGO name Mascot score Coverage Description
%
HSP90AB1 2,178 
300
44 
8
Heat shock 90-kD protein 1, 
HSP90AA1 1,668 
151
35 
6
Heat shock 90-kD protein 1, 
HSPA8 1,338 39 Heat shock 70-kD protein 8 isoform 1
HSPA6 327 8 Heat shock 70-kD protein B
AHSA1 81 
27
3 
9
AHA-1 activator of heat shock 90-kD protein ATPase homologue 1
DNAJA1 212 26 Hsp40 homologue, subfamily A, member 1
PSMD2 242 14 Proteasome 26S non-ATPase subunit 2
PSMD1 105 2 Proteasome 26S non-ATPase subunit 1
PSMD6 105 
46
5 
6
Proteasome 26S non-ATPase subunit 6
PSMC2 75 3 Proteasome 26S ATPase subunit 2
Proteins with two rows of data were identified in two independent experiments. The gel from one of the experiments is shown in Fig. 1 A. A threshold Mascot score of 50 was 
used as cut-off, indicating a 95% confidence of being a true identification. For AHSA1, in the second experiment, the mass spectrometry profile was manually examined to 
confirm the reliability of the observation.2754 Hsp90 determines AID protein abundance | Orthwein et al.
functional interaction between AID and Hsp90 is physio-
logically relevant.
To use a more sensitive assay to monitor AID decay at shorter 
times and to be able to compare AID variants, we established 
stable Ramos transfectants expressing various AID-GFP con-
structs from a heterologous promoter. The levels of AID-GFP 
could thus be monitored over time and accurately quantified by 
flow cytometry. We confirmed that AID-GFP but not GFP was 
destabilized upon Hsp90 inhibition in these cell lines with ki-
netics consistent to that observed for endogenous AID (Fig. 2 D). 
This indicated a direct action on AID protein rather than on 
Aicda transcription, which was confirmed by Northern blot of 
Aicda in Ramos cells (unpublished data). As would be expected, 
the AID-A2 chimeras that did not interact with Hsp90 were in-
sensitive to GA treatment (Fig. 2 D). Treatments inhibiting or 
(17-AAG; Prodromou et al., 1997; Stebbins et al., 1997; 
Panaretou et al., 1998; Young and Hartl, 2000). Treating 
Ramos cells with GA prevented the interaction of AID-
GFP with Hsp90, as indicated by the lack of coimmuno-
precipitation (Fig. 2 A). More importantly, treatment of 
human, chicken, and mouse B cell lymphoma lines with 
GA caused a clear reduction in the levels of endogenous 
AID at 12 and 24 h. We probed for the known Hsp90 client 
kinase Lck, which was also reduced, as positive control 
(Giannini and Bijlmakers, 2004). Other enzymes involved 
in antibody diversification, including UNG (uracil-DNA 
N-glycosylase) and MSH6, were not sensitive to Hsp90 in-
hibition (Fig. 2 B). Finally, endogenous AID in stimulated 
human primary B cells from multiple donors was also sen-
sitive to Hsp90 inhibition (Fig. 2 C), confirming that the 
Figure 2.  Hsp90 actively maintains the steady-state levels of AID. (A) Ramos cells stably expressing AID-GFP or GFP alone were treated with 2 µM 
GA (+) or DMSO () for 2 h. Anti-GFP immunoprecipitates (IP) were fractionated on SDS-PAGE, and blots were probed with anti-Hsp90 and anti-GFP. 
Aliquots (5%) of the whole cell lysates were probed to control for Hsp90 expression. One of two independent experiments is shown. (B) Human Ramos, 
mouse CH12F3-2 (pretreated for 16 h with IL-4, TGF-1, and anti-CD40 to induce AID expression), and chicken DT40 B cell lines were treated with 2 µM 
GA (+) or DMSO () and harvested at the indicated time points after GA. The expression level of the indicated proteins was analyzed by Western blot 
(WB) in total or nuclear (where indicated) extracts. Identical effect was observed with 17-AAG in all cell lines (not depicted). Representative panels from 
one of two or three independent experiments (depending on the antibody) are shown. (C) Resting B cells purified from blood of three donors were acti-
vated with IL-4 and anti-CD40 and 4 d later treated and analyzed as in B except that the Hsp90 inhibitor 17-AAG (+) was used instead of GA. (D) Ramos 
cells stably expressing GFP, AID-GFP, or chimeras AID-A2 #1 or #2 were treated in triplicate with 2 µM GA or DMSO. The GFP mean fluorescence intensity 
(MFI) was monitored by flow cytometry and normalized to t0 = 100%. MFI ± SD is plotted over time. One of three independent experiments is shown  
(**, P < 0.01). (E) AID-GFP was monitored as in D except that Ramos cells were pretreated with 100 ng/ml CHX for 30 min before Hsp90 inhibition. One of 
five independent experiments is shown (**, P < 0.01). (F) Purified naive B cells from Aicda/ mice were activated and retrovirally transduced with mouse 
AID-GFP or GFP control. Cells were analyzed as in D 2 d after transduction. One of three independent experiments is shown (**, P < 0.01).JEM VOL. 207, November 22, 2010 
Article
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results could be explained by increased AID 
nuclear  import  after  Hsp90  inhibition  and 
therefore AID destabilization in the nucleus 
(Aoufouchi et al., 2008). However, we did not 
observe any changes in AID localization after 
Hsp90 inhibition, even when combined with 
a proteasome inhibitor to prevent degradation of nuclear 
AID (Fig. S3). So, we compared the effects on AID-GFP   
of inhibiting Hsp90 versus inhibiting nuclear export with 
leptomycin  B  (LMB),  which  enriches AID-GFP  in  the   
nucleus (Ito et al., 2004; McBride et al., 2004), in the stable 
Ramos transfectants. The kinetics of AID-GFP decay after 
GA or LMB treatment were different (Fig. 3 A). Combined 
GA  and  LMB  treatment  showed  an  apparently  additive   
effect (Fig. 3 A). Similar results were obtained using DT40 
and HeLa cells stably expressing AID-GFP (Fig. S4). The 
lack of detectable nuclear translocation of AID after Hsp90 
inhibition, together with the different decay kinetics after 
GA and LMB, raised the possibility that AID degradation 
after each of these treatments happened in different com-
partments and therefore would involve different pathways. 
To  test  this,  we  used  Ramos  cells  expressing  GFP-AID   
because the N-terminal GFP fusion blocks nuclear import 
of AID (Patenaude et al., 2009) but not its binding to Hsp90 
(Fig. S1 E). Consistently, with its exclusively cytoplasmic 
localization, GFP-AID did not respond to LMB, but it was 
still sensitive to GA (Fig. 3 B). Hsp90 clients are in dynamic 
exacerbating PKA activity had no effect on the sensitivity of 
AID-GFP to GA, further suggesting that these two pathways are 
not connected (Fig. S2). We then measured the decay kinetics of 
AID-GFP after pretreating the cells with cycloheximide (CHX) 
so as to follow the pool of AID that had already been synthe-
sized and not the nascent AID that might be more sensitive to 
folding requirements. CHX caused the expected decay of AID-
GFP (compare control DMSO-treated AID-GFP levels in Fig. 2, 
D vs. E), which was clearly accelerated by GA (Fig. 2 E), indicat-
ing a role for Hsp90 in stabilizing fully synthesized AID. We 
confirmed that both mouse and human AID-GFP were similarly 
sensitive to Hsp90 inhibition when expressed in AID-deficient 
mouse primary splenic B cells (Fig. 2 F and not depicted), thus 
ruling out any effect of the transformed cell environment of 
Ramos on our observations. We conclude that functional Hsp90 
is necessary to stabilize and maintain the steady-state levels of 
AID in vivo in primary as well as in transformed cells.
Hsp90 protects cytoplasmic AID from being degraded
Binding to Hsp90 can regulate protein subcellular localiza-
tion (DeFranco, 1999; Galigniana et al., 2004). Indeed, our 
Figure 3.  Cytoplasmic ubiquitination and protea-
somal degradation of AID after Hsp90 inhibition.  
(A) Ramos cells stably expressing AID-GFP were treated 
in triplicate with DMSO, 2 µM GA, and/or 50 ng/ml LMB, 
and the GFP signal was monitored over time by flow 
cytometry. The MFI normalized to t0 = 100% ± SD is plot-
ted for each treatment (**, P < 0.01). One of five indepen-
dent experiments is shown. (B) Ramos cells stably 
expressing GFP-AID, which is completely impaired for 
nuclear import (Patenaude et al., 2009), were analyzed as 
in A. One of three independent experiments is shown.  
(C) Ramos cells stably expressing AID-GFP were pre-
treated or not for 30 min with 10 µM MG132 before 
adding DMSO or 2 µM 17-AAG and analyzed as in A  
(**, P < 0.01). One of five independent experiments is shown. 
(D) Human Ramos and chicken DT40 B cell lines were 
treated with 2 µM GA. Where indicated, 10 µM MG132 
was added only during the last 12 h of incubation to 
avoid excessive cell death. Cells were harvested at differ-
ent time points, lysed, and analyzed by Western blot 
(WB). One of two independent experiments is shown for 
each cell line. (E) Ramos B cells stably expressing human 
AID-GFP or primary mouse B cells transduced with 
mouse AID-GFP were pretreated with 10 µM MG132 for 
30 min before addition or not of 2 µM GA for 5 h. Anti-
GFP immunoprecipitates (IP) were analyzed by Western 
blot using anti-ubiquitin (Ub) and anti-GFP. Polyubiqui-
tinated AID was quantified by densitometry, and the 
relative means ± SD were plotted for three independent 
experiments for each cell type.2756 Hsp90 determines AID protein abundance | Orthwein et al.
but not of ATM (ataxia telangiectasia mutated), which is 
not an Hsp90 client. Altogether, these results indicate that 
cytoplasmic AID requires constant stabilization by Hsp90 
and that altering the balance of this reaction, either by in-
hibiting  Hsp90  or  favoring  the  degradative  side  of  this 
pathway through CHIP overexpression, leads to greatly di-
minished AID protein levels through proteasomal degrada-
tion in the cytoplasm.
Inhibition of Hsp90 results in reduced antibody diversification
We first used the chicken B cell lymphoma line DT40 to mon-
itor AID-dependent antibody diversification by gene conver-
sion. The frequency of Ig gene conversion is estimated by using 
a DT40 line with a frameshift mutation in the IgV gene that 
prevents surface IgM expression. Some gene conversion events 
correct this frameshift, restoring IgM expression. The median 
percentage of IgM+ cells generated during expansion of several 
initially IgM populations is proportional to the rate of Ig gene 
conversion (Arakawa et al., 2002). The problem is that Hsp90 is 
essential for eukaryotic cells (Borkovich et al., 1989; Cutforth 
and Rubin, 1994), which precludes its genetic ablation or com-
plete inhibition. However, we observed that AID decay after 
Hsp90 inhibition was dose dependent (Fig. S4 C for GA and 
not depicted for 17-AAG). We used 17-AAG for these assays 
because we found it to be less toxic than GA for lymphocytes 
(unpublished data). Low doses of 17-AAG had minimal impact 
on DT40 cell growth but still caused a robust decrease in AID 
protein levels (Fig. 5 A). This partial reduction in AID levels was 
proportional to a reduction in Ig gene conversion (Fig. 5 A).   
In similar experiments using a DT40 line that diversifies the 
IgV by SHM (Arakawa et al., 2004), we could also confirm a 
reduction in SHM (this time by monitoring the appearance of 
equilibrium  with  proteasomal  degradation  (Pearl  and   
Prodromou, 2006). Indeed, the proteasome inhibitor MG132 
prevented  the  Hsp90  inhibition–induced  degradation  of 
AID-GFP as well as of endogenous AID in Ramos and 
DT40 cells (Fig. 3, C and D; and Fig. S4 A). We obtained 
identical  results  using  lactacystin,  another  proteasome   
inhibitor  (unpublished  data). A  reproducible  3.5-fold   
increase in AID polyubiquitylation was observed in Ramos 
and  primary  mouse  B  cells  after  combined  Hsp90  and   
proteasome  inhibition  versus  inhibiting  only  the  protea-
some (Fig. 3 E). This was not particular to B cells because it 
was also true for AID-GFP in stably transfected HeLa cells 
(unpublished  data). These  experiments  show  that  Hsp90 
stabilizes cytoplasmic AID by protecting it from protea-
somal degradation.
The E3 ubiquitin ligase CHIP (C terminus of Hsc70- 
interacting  protein)  is  physically  associated  with  Hsp90 
and triages many Hsp90 clients (McDonough and Patterson, 
2003). Of note, CHIP is constitutively expressed in Ramos 
and induced upon activation in primary mouse B cells 
(Fig. S1, B and C). Furthermore, CHIP coimmunoprecipi-
tated  with AID-GFP  from  extracts  of  stably  transfected 
HeLa cells (Fig. 4 A). The interaction was only apparent 
when the cells were pretreated with a proteasome inhibi-
tor, which allows the accumulation of this rapid turn over 
interaction (Li et al., 2004). We reasoned that if Hsp90   
was normally stabilizing AID in B cells, the overexpression 
of CHIP could reduce AID levels by shifting the equilib-
rium of the pathway from stabilization to degradation. In-
deed, all subclones from three independent transfectants of   
Ramos B cells overexpressing Myc-CHIP showed a signif-
icantly reduced steady-state level of AID (Fig. 4, B and C) 
Figure 4.  The Hsp90-associated E3 ubiq-
uitin ligase CHIP can destabilize AID.  
(A) HeLa cells stably expressing AID-GFP were 
transfected with Myc-CHIP and 48 h later 
treated for 5 h with DMSO (), 2 µM GA,  
50 ng/ml LMB, and/or 10 µM MG132 (30-min 
pretreatment) in the indicated combinations. 
Anti-GFP immunoprecipitates (IP) were ana-
lyzed by Western blot (WB) with anti-GFP and 
anti-Myc. Aliquots (5%) of the total cell  
lysates were used to control for Myc-CHIP  
expression. One of two independent  
experiments is shown. (B) Endogenous AID 
was analyzed by Western blot in single cell 
subclones from untransfected control or three 
independent Myc-CHIP Ramos transfectants 
(CL11, CL24, and CL25) after expansion. ATM 
was used as an Hsp90-independent control, 
antiactin as loading control, and anti-Myc to 
confirm the expression of CHIP. Three repre-
sentative subclones from each transfectant 
are shown. The vertical black line indicates 
that intervening lanes have been spliced out. (C) AID protein levels in all control or Myc-CHIP Ramos subclones (distinguished by different symbols) were 
estimated from nonsaturated Western blots. The signal was normalized to each corresponding actin signal obtained from equivalent exposures and plot-
ted. Median values are indicated (**, P < 0.01).JEM VOL. 207, November 22, 2010 
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efficiency of switching between cells that have undergone the 
same number of cell divisions, accounting for any cell growth 
defect that continuous exposure to 17-AAG could cause. There 
was a clear and dose-dependent reduction in CSR caused by 
17-AAG, overall and for each cell division tested (Fig. 5 D).   
Alternatively, we performed a 12-h treatment with higher doses 
of 17-AAG, after which the drug was removed (Fig. 6 A).   
A drastic reduction in CSR to IgA was observed when the 
sIgM-loss cells from originally sIgM+ populations but also by   
direct IgV sequencing) that was proportional to the decrease 
in AID protein levels (Fig. 5, B and C). We then analyzed the 
effect  of  Hsp90  inhibition  on  CSR  by  using  the  mouse 
CH12F3-2 cell line, which efficiently switches from IgM to 
IgA after cytokine stimulation (Nakamura et al., 1996). Because 
these assays take place over a few days, we used CFSE staining 
to monitor cell proliferation. Thus, we could compare the   
Figure 5.  Reduced antibody diversification in chicken and mouse B cells chronically treated with Hsp90 inhibitors. (A) The rate of Ig gene 
conversion in DT40 cells was estimated from the proportion of sIgM-gain cells arising from sIgM populations after 3 wk of expansion in the presence of 
DMSO (Ctrl) or two different concentrations of 17-AAG. The proportion of sIgM+ cells for each population and the median values are indicated (left). The 
level of AID protein was quantified by densitometry from nonsaturated Western blots for each population at the end of the experiment and normalized to 
actin levels. Mean ± SD values for all populations grown in each condition are plotted (middle). The effect of 17-AAG on DT40 growth was monitored by 
calculating the total number of cells in a culture originating from 105 cells (right). Mean ± SD of triplicate cultures are plotted over time. (B) SHM was 
monitored in analogous experiments to A except that a sIgM+ V AIDR DT40 cell line, which cannot undergo gene conversion and instead uses SHM to 
diversify the Ig genes, was used. IgM-loss cells arise as a consequence of SHM with a certain frequency, and so the proportion of sIgM-loss cells arising 
over time provides an estimate of SHM rate (Arakawa et al., 2004). (C) DNA was extracted from control or 0.1 µM 17-AAG–treated unsorted cultures  
from B after equal expansion. The IgV was PCR amplified and sequenced. The fraction of sequences containing the indicated number of mutations is plotted  
in the pie chart with the number of sequences analyzed indicated in the center. The calculated mutation frequency (mutations/base pair) is indicated 
under each pie chart. (D) CH12F3-2 mouse B cells stimulated with IL-4, TGF-1, and agonist anti-CD40 were cultured with DMSO (Ctrl) or the indicated 
concentrations of 17-AAG. The cells were stained with CFSE before activation to follow cell divisions. Representative plots of the proportion of IgA+ cells 
in each population after 3 d (left) and CFSE profiles (middle) are shown. For each cell division, the proportion of sIgA+ cells was calculated, and the results 
from four independent experiments are summarized in the plot as the mean ± SD values (right). In all panels: *, P < 0.05; **, P < 0.01.2758 Hsp90 determines AID protein abundance | Orthwein et al.
(Klemm et al., 2009). We transduced the BCR-ABL1+ K562 
cell line with AID-ires-GFP or GFP control retroviruses and, 
for  each  construct,  prepared  mixed  populations  with  un-
infected (GFP) cells at a defined ratio. Mutations in BCR-
ABL1 that confer resistance are selected by culturing the cells 
in the presence of imatinib. This is readily observed by flow 
cytometry as an increased ratio of GFP+/GFP cells over 
time. Indeed, we observed a higher proportion of GFP+ cells 
within 2–3 wk only in AID-expressing cells that were grow-
ing in the presence of imatinib (Fig. 7 A). This was AID de-
pendent as it was not observed in GFP control cultures, and 
the imatinib-resistant cells appeared earlier in cultures ex-
pressing higher levels of AID (Fig. 7, A and B). More relevant 
to our purpose, the AID-dependent change in the GFP+/
GFP ratio was fully prevented by a very low dose of 17-AAG 
(Fig. 7 A). Treatment with this dose of 17-AAG visibly re-
duced AID but not BCR-ABL1 protein levels by day 7 
(Fig. 7 C). We confirmed that 17-AAG prevented the AID-
mediated increase in imatinib IC50 (Fig. 7 D). We also directly 
checked for mutations by sequencing BCR-ABL1. An in-
crease in point mutations (many of them known to induce 
imatinib resistance; Klemm et al., 2009) could be detected in 
CH12F3-2 cells were treated with 17-AAG at day 1 after 
stimulation, coincident with the time when the peak of AID 
protein was observed (Fig. 6, B and C). As would be expected, 
17-AAG treatment at day 2 had a less but still statistically signif-
icant effect on CSR. Importantly, we obtained identical results 
in switching assays using normal mouse splenic B cells (Fig. 6 D). 
A drastic decrease of CSR to IgG1 was observed when cells 
were  treated  with  17-AAG  at  day  1  after  stimulation. This 
higher dose of 17-AAG delayed growth of primary B cells, but 
the effect on CSR was nevertheless very clear when comparing 
the efficiency of switching per cell division. Again, treating the 
cells at day 2 after stimulation caused a smaller but statistically 
significant effect. As expected, treating the cells at day 3 had no 
effect on the efficiency of CSR measured at day 4 (unpublished 
data). We  conclude  that  cytoplasmic AID  degradation  after 
Hsp90 inhibition has a direct and proportional effect on all anti-
body diversification mechanisms.
Hsp90 inhibition prevents off-target mutation by AID
We assayed AID off-target mutation using the recently de-
scribed role of AID in generating resistance of the onco-
genic kinase BCR-ABL1 to the drug imatinib in CML cells   
Figure 6.  Acute inhibition of Hsp90 impairs CSR in mouse B cells. (A) Scheme of the experimental strategy fort treatment of CH12F3-2 B cells or 
primary naive mouse splenic B cells. D, day; FC, flow cytometry. (B) Kinetics of AID protein expression in CH12F3-2 mouse B cells determined by Western 
blot (WB) at different times after stimulation. One of two independent experiments is shown. (C) CH12F3-2 B cells were stained with CFSE and stimulated 
with IL-4, TGF-1, and anti-CD40 to switch to IgA. Either at day 1 or 2 after activation, the cells were treated for 12 h with 2 µM 17-AAG and then re-
turned to normal medium. The proportion of sIgA+ cells per cell division determined by flow cytometry is plotted under each cell division in the corre-
sponding CFSE plot for a representative experiment (left). The mean proportions of sIgA+ cells for each cell division ± SD from four independent 
experiments are plotted (right; **, P < 0.01). (D) Purified mouse naive splenic B cells were loaded with CFSE and stimulated with IL-4 and LPS to induce 
switching to IgG1. Either at day 1 or 2 after activation, the cells were treated with 17-AAG and then returned to normal medium. The proportion of 
sIgG1+ cells per cell division was determined and presented as in C. Data from one representative mouse are shown (left), and pooled data from five mice 
are plotted (right). To be able to compare all the mice accounting for the inter assay variability, data points were normalized with the percentage of IgG1+ 
cells in cell division 3 of the control set as 1 (*, P < 0.05; **, P < 0.01). Ctrl, control.JEM VOL. 207, November 22, 2010 
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Figure 7.  Hsp90 inhibition reduces AID off-target mutations. (A) BCR-ABL1+ K562 cells were transduced with GFP control (insets) or AID-ires-GFP 
retroviral vectors. Mixed populations of transduced (GFP+) and uninfected (GFP) cells were cultured in the presence of DMSO, 2 µM imatinib, 2 µM  
imatinib plus 0.1 µM 17-AAG, or 0.1 µM 17-AAG, and the proportion of GFP+ cells was determined periodically by flow cytometry. Data are plotted as the 
mean GFP+/GFP ratio from triplicate populations ± SD, relative to the initial ratio set as 1. Two independent experiments are shown differing only in AID 
protein level expression from having or not a consensus Kozak sequence before the AID start codon. (B) Western blot (WB) of parental K562 cells () and 
sorted GFP+ populations transduced with pMX-AID-ires-GFP vectors differing only in the presence of the Kozak sequence. AID was detected using anti-
AID, and antiactin was used as loading control. (C) Sorted GFP+ cells transduced or not with pMX-KozakAID-ires-GFP vectors as in A were cultured with 
0.1 µM 17-AAG for the indicated times. The levels of the indicated proteins were analyzed by Western blot in total extracts using anti-AID and anti-ABL1. 
One of two independent experiments is shown. (D) GFP+ K562 populations were sorted after expansion from A. Cell viability after culture for 2 d with 
different concentrations of imatinib was determined using an MTS reduction colorimetric assay. The relative mean OD at 490 nm ± SEM of duplicate wells 
(untreated cells = 100%) is plotted for each concentration for cell populations transduced with pMXs-KozakAID-ires-GFP that had been treated in A with 
DMSO, imatinib, imatinib plus 0.1 µM 17-AAG, or 17-AAG. The parental K562 cells were included in this assay. One of two independent experiments is 
shown. (E) BCR-ABL1 (exon 13 of BCR and exon 9 of ABL1) was PCR amplified from cells expressing GFP control or AID-ires-GFP and expanded under the 
indicated conditions. Mutations, determined relative to the consensus of all sequences, are indicated on schemes of the 700-bp ABL1 region that was 
directly sequenced from the PCR product. Thin vertical bars represent mutations at A:T bp, whereas thick bars represent mutations at C:G pairs. Mutations 
previously described to confer imatinib resistance (Branford and Hughes, 2006) are identified by an asterisk and indicated below the sequence stack.2760 Hsp90 determines AID protein abundance | Orthwein et al.
Table II.  BCR-ABL1 mutations in K562 cells
Construct transduced Treatment BCR-ABL1 sequence analysis Number of clones/total Amino acid change
GFP Imatinib Unmutated 6/8 No changes
894 CTA to CTG 1/8 Silent
1062 CTA to CTG 1/8 Silent
AID-ires-GFP Control Unmutated 7/9 No changes
894 CTA to CTG 1/9 Silent
1062 CTA to CTG 1/9 Silent
AID-ires-GFP Imatinib Unmutated 2/10 No changes
894 CTA to CTG 3/10 Silent
944 ACT to ATT 4/10 T315I
1062 CTA to CTG 2/10 Silent
1334/1335 CGT to CTG 1/10 R445L
1356 CTA to CTG 2/10 Silent
1375 GAG to AAG 3/10 E459K
AID-ires-GFP Imatinib + 17-AAG Unmutated 6/9 No changes
894 CTA to CTG 1/9 Silent
1062 CTA to CTG 2/9 Silent
Identity of the mutations indicated in the diagram in Fig. 7 E. The BCR-ABL1 (exon 13 of BCR and exon 9 of ABL1) was RT-PCR amplified from single cell clones, and a 
fragment of 700 bp in the ABL1 kinase domain was directly sequenced. The number to the left of the mutation indicates the mutated position with respect to the ABL1 
open reading frame. The mutated base is underlined within the affected codon. Mutations at C:G pairs and amino acid substitutions previously described to confer clinical 
imatinib resistance (Branford and Hughes, 2006) are highlighted in bold.
AID-expressing K562 cells growing in imatinib. In contrast, the 
mutation level in AID-expressing cultures that were jointly 
treated with imatinib and 17-AAG was indistinguishable from 
the GFP control (Fig. 7 E and Table II).
DISCUSSION
We identify and characterize herein the constitutive stabiliza-
tion of AID by the Hsp90 chaperone pathway. Our results 
show that Hsp90 largely determines the overall steady-state 
levels of functional AID protein. Although Hsp90 may also 
contribute to the biogenesis of AID, its key function appears 
to be the stabilization of the protein. This is well in accor-
dance with the major role of Hsp90 in protecting the func-
tional competence of many of its clients, beyond simply 
assisting with their de novo folding (Jakob et al., 1995; Nathan 
et al., 1997; Whitesell and Lindquist, 2005; Pearl and Prodromou, 
2006; Picard, 2006; Wandinger et al., 2008). This is a new mecha-
nism positively regulating AID-mediated antibody diversifi-
cation that seems evolutionarily conserved, as we find it in 
chicken, mouse, and human B cells.
The molecular details of AID stabilization in the cyto-
plasm are likely incomplete because many proteins modu-
late the Hsp90 pathway (Young et al., 2004; Wandinger et al., 
2008). However, our experimental evidence, together with 
the identification of members of the Hsp90 chaperone path-
way that consistently copurified with AID (Table I), suggests 
a working model in which AID would be regulated similarly 
to the steroid hormone receptors (Picard, 2006). These re-
ceptors first form an early complex with the Hsp70/Hsp40 
chaperone/cochaperone, to which Hsp90 and other factors 
are then recruited. Consecutive cycles of chaperoning are in 
dynamic equilibrium with proteasomal degradation unless 
the receptor is stabilized by ligand binding and translocates 
to the nucleus (Whitesell and Lindquist, 2005; Picard, 2006). 
Consistent with this model, we found HSPA8, the major con-
stitutively expressed form of Hsp70, among the AID-Flag/
HA–interacting partners in Ramos B cells. The same iso-
form has been found using tagged AID expressed in HEK293 
cells (Wu et al., 2005). Hsp40 proteins are the first agents in 
the Hsp70/Hsp90 chaperone pathway (Kimura et al., 1995; 
Hernández et al., 2002). We identified and have confirmed 
the functional interaction of AID with a defined subset of 
Hsp40 proteins, which will be reported elsewhere (unpub-
lished  data). AID  stabilization  requires  the ATP  hydrolysis   
cycle of Hsp90, and the cochaperone AHA-1, which stimulates 
the ATPase activity of Hsp90 (Panaretou et al., 2002; Lotz   
et al., 2003), also copurified with AID. As is the case for ste-
roid hormone receptors, we show that cytoplasmic AID exists 
in a dynamic equilibrium between stabilization and protea-
somal degradation. Indeed, inhibiting Hsp90 or overexpress-
ing the Hsp90-associated ubiquitin ligase CHIP (Connell et al., 
2001; McDonough and Patterson, 2003) can shift the bal-
ance toward AID degradation. Stabilization seems to be the 
predominant pathway because simultaneous inhibition of the 
proteasome and Hsp90 leads to the accumulation of much 
higher levels of polyubiquitinated AID than only proteasome 
inhibition. However, it remains possible that the destabilizing 
side of this pathway contributes to limit AID levels, which we 
are exploring. It is interesting that AID seems to be uniquely 
dependent on Hsp90 when compared with its paralogue pro-
teins, the APOBEC family. The intrinsic instability of uncom-
plexed AID probably helps to limit its mutagenic potential. 
This fits nicely with a study showing that the half-life of AID   
is highly reduced in the nucleus compared with the cytoplasm JEM VOL. 207, November 22, 2010 
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Finally, the Hsp90-mediated mechanism stabilizing AID is 
operative in lymphoma-derived cell lines as well as in cells 
with ectopic overexpression of AID. The relative Hsp90 de-
pendence of AID in transformed versus normal cells remains 
to be studied. Nevertheless, our findings offer the first possi-
bility of pharmacologically manipulating AID protein levels 
to prevent off-target mutation. We provide proof of principle 
that this is possible in a CML cell line model. A very low dose 
of Hsp90 inhibitor completely abrogated BCR-ABL1 muta-
tions and imatinib resistance. AID-generated lesions in non-
Ig genes are widespread but much less frequent than at the   
Ig genes (Liu et al., 2008; Robbiani et al., 2009). Indeed, the AID-
generated breaks in c-Myc seem to be limiting for the on-
cogenic  c-Myc–IgH  chromosomal  translocations  (Robbiani   
et al., 2008, 2009). Therefore, it might be possible that very 
low doses of Hsp90 inhibitors have a disproportionate effect 
on the frequency of oncogenic lesions versus antibody diver-
sification. It would be worth exploring whether the Hsp90 
inhibitors that are currently being tested in the clinic could 
be useful in treating those cancers in which AID contributes 
to disease progression (Matsumoto et al., 2007; Pasqualucci   
et al., 2008; Klemm et al., 2009).
MATERIALS AND METHODS
DNA constructs. The pEGFP-N3–based (Takara Bio Inc.) expression vec-
tors for human AID-GFP, AID FYRN-GFP, AID-Flag/HA, APOBEC2, and 
AID-APOBEC2 chimeras have been described previously (Patenaude et al., 
2009). Rat APOBEC1 and human APOBEC3G cloned in pEGFP-C3 as 
well as human AID T27A/T38A, which was subcloned into pEGFP-N3, 
were gifts from S. Conticello (Istituto Toscano Tumori, Florence, Italy;   
Conticello et al., 2008). To construct N-terminally Flag-tagged versions of 
APOBEC1, APOBEC2, and APOBEC3G, enhanced GFP (EGFP) was ex-
cised NheI–XhoI from pEGFP-C3 and replaced by the annealed oligonucle-
otides AO1 and AO2. To construct C-terminally Flag-tagged versions of 
some of the proteins, EGFP was excised EcoRI–NotI from pEGFP-N3 and 
replaced by the annealed oligonucleotides OJ215 and OJ216. AID was sub-
cloned as an NheI–NotI fragment under the weaker EF1- promoter in pEF. 
AID-APOBEC2 chimeras #1 and #2 were excised from pTrc99a (Patenaude 
et al., 2009) by partial digestion with NotI and EcoRI and subcloned into the 
pMXs retroviral vector. Untagged hAID in pMXs-ires-GFP has been de-
scribed previously (Patenaude et al., 2009). Mouse AID (from R. Harris, 
University of Minnesota, Minneapolis, MN) was subcloned EcoRI and NotI 
into pMXs. Flag-human Hsp90- was inserted as a KpnI–NotI fragment 
into pcDNA3.1. Myc-human Hsp90- in pCMV-3Tag2 was a gift of   
J.-.P Gratton (Institut de Recherches Cliniques de Montréal, Montréal, Québec, 
Canada). Construct names throughout the manuscript indicate the actual   
order of the fragments in fusion proteins.
Reagents and antibodies. Stock aliquots of 2 mM GA, 2 mM 17-AAG,   
5 mM H-89, and 25 mM forskolin (LC Laboratories) as well as 50 mM 
IBMX (3-isobutyl-1-methylxanthine; Sigma-Aldrich) were made in DMSO. 
Stocks of 5 mM MG132 (EMD) and 25 µg/ml LMB (LC Laboratories) were 
made in ethanol. CHX (Sigma-Aldrich) was freshly prepared before each ex-
periment 100 mg/ml in ethanol. Stock of 2 mM imatinib (Gleevec; Novartis) 
in PBS was a gift of T. Moroy and C. Khandanpur (Institut de Recherches 
Cliniques de Montréal). All drugs were stored at 20°C protected from light. 
Antibodies and dilutions used were as follows: 1:3,000 anti–EGFP–horseradish 
peroxidase (HRP; Miltenyi Biotec), 1:3,000 anti–Myc-HRP (Miltenyi Bio-
tec), 1:3,000 anti–Flag-HRP (Sigma-Aldrich), 1:3,000 anti-Hsp90 (sees both 
isoforms;  BD),  1:1,000  anti–Hsp90-  and  1:1,000  anti–Hsp90-  (Stress-
Marq), 1:1,000 anti-AID (Cell Signaling Technology) for human and chicken 
AID and 1:500 anti-mAID (a gift from F. Alt, Harvard University, Boston, 
(Aoufouchi et al., 2008). We speculate that AID, just as the 
steroid hormone receptors (Whitesell and Lindquist, 2005; 
Picard, 2006), might undergo some conformational change 
to dissociate from Hsp90. An attractive possibility is that 
oligomerization  stabilizes AID,  thus  emancipating  it  from 
Hsp90. In line with this, the Hsp90-interacting domain of 
AID comprises most of its proposed dimerization interface 
(Prochnow et al., 2007; Patenaude et al., 2009), and an oligo-
merization-deficient AID mutant can still bind to Hsp90. We 
have proposed that dimerization/oligomerization of AID is 
important for its cytoplasmic retention and nuclear import 
(Patenaude et al., 2009). However, at variance with the es-
trogen receptor, Hsp90 does not seem to play a major role in 
AID cytoplasmic retention. We must hypothesize that AID 
forms part of another cytoplasmic complex that fulfills this 
role. This Hsp90-independent fraction of AID might explain 
the slower kinetics of AID degradation in Ramos cells after 
Hsp90 inhibition compared with other Hsp90 clients such as 
Lck (Giannini and Bijlmakers, 2004).
The interaction of AID with Hsp90 has major functional 
consequences. Hsp90 stabilizes many proteins, and part of the 
effect observed on antibody diversification after inhibiting 
Hsp90 could formally be indirect. However, there is a nega-
tive dose–response relationship between AID protein levels 
and Hsp90 inhibition, which correlates with a proportional 
decrease in antibody diversification. This observation argues 
for a direct effect. Furthermore, Hsp90 inhibition affected all 
AID-dependent pathways: SHM, CSR, and Ig gene conver-
sion as well as off-target mutation. All of these pathways are 
initiated by DNA deamination by AID followed by uracil 
processing by either UNG or MSH2/MSH6, which were not 
affected by Hsp90 inhibition. Downstream from there, these 
pathways diverge (i.e., trans-lesion synthesis for mutations, 
homologous recombination for gene conversion, and non-
homologous end joining for CSR), so a direct effect on AID   
is much more likely than an independent effect on each of 
these pathways. By stabilizing the bulk of AID, the Hsp90 
pathway determines the availability of functional AID. Indeed,   
AID-catalyzed DNA deamination at the Ig loci was directly 
proportional to the overall level of AID protein remaining   
after Hsp90 inhibition. This is in agreement with the previ-
ously reported AID dose effect on the efficiency of antibody 
diversification (de Yébenes et al., 2008; Dorsett et al., 2008; 
Sernández et al., 2008; Takizawa et al., 2008; Teng et al., 
2008). Together with our findings, these observations suggest 
that the ratio of nuclear to cytoplasmic AID is constant. Thus, 
decreasing the overall level of AID would lead to a propor-
tional decrease in the nuclear fraction and biological activity 
of AID. Otherwise, if AID were particularly abundant in the 
nucleus at any stage, a 50% decrease in total AID protein 
caused by partial Hsp90 inhibition (or by haploinsufficiency) 
would not necessarily lead to a proportional decrease in 
antibody diversification. Our work highlights the intimate 
relationship between the mechanisms of AID subcellular   
localization and protein stability (Aoufouchi et al., 2008;   
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Coimmunoprecipitation  and Western  blot. HEK293T cells cotrans-
fected at a 1:1 ratio with GFP and Myc or Flag-tagged proteins were homog-
enized in lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol,   
2 mM EDTA, 1% Triton X-100, and 20 mM NaF) 48 h after transfection and 
immunoprecipitated with anti-Flag M2 affinity gel as described previously 
(Patenaude et al., 2009). Immunoprecipitation of GFP-tagged proteins   
were performed using the MACS GFP Isolation kit (Miltenyi Biotech)   
according to the manufacturer’s instructions. Where indicated, cells were 
treated with 10 µM MG132 for 30 min and/or 2 µM GA or DMSO for   
5 h before lysis. The eluates and lysates were analyzed by Western blot devel-
oped  with  SuperSignal West  Pico  Chemiluminescent  substrate  (Thermo 
Fisher Scientific).
AID stability assays. The GFP signal of cell lines expressing AID-GFP 
variants was measured by flow cytometry at various time points after the in-
dicated treatments. Dead cells were excluded by propidium iodide staining. 
For endogenous AID, 5 × 106 Ramos, DT40, or K562 cells in 5 ml of culture 
medium were treated with GA or 17-AAG, and aliquots of 1.5–2 × 106 cells 
were harvested at various time points. Alternatively, 2 × 106 CH12F3-2 cells 
(a gift of T. Honjo through A. Martin [University of Toronto, Toronto, Ontario, 
Canada]; Nakamura et al., 1996) were stimulated with 2 ng/ml recombinant 
human TGF-1 (R&D Systems), 20 ng/ml recombinant murine IL-4 (Pepro-
Tech), and 5 µg/ml functional grade purified anti–mouse CD40 (BD) for 16 h 
before GA treatment. Human primary B cells at 2 × 106/ml were treated 
with 2 µM 17-AAG 72 h after activation, and aliquots of 106 cells were har-
vested at various time points. Cells were washed once with PBS and lysed in 
SDS-PAGE sample buffer. Lysates were analyzed by Western blotting.
Monitoring antibody diversification. AID-mediated Ig gene conversion 
was estimated in DT40 cre1 cells by scoring the frequency of sIgM-gain 
phenotype, which is directly proportional to the frequency of repair of a 
frameshift in the IgV by gene conversion (Arakawa et al., 2002). DT40 
sIgM  cell  populations  were  FACS  sorted,  and  confluent  cultures  were 
grown in 24-well plates with Hsp90 inhibitors. This method was favored over 
using single cell clones because of the effect of Hsp90 inhibition on single 
cells growth. Cells were grown for 3 wk at 41°C in the presence of the in-
hibitors, and the surface IgM phenotype was measured by flow cytometry as 
described previously (Di Noia and Neuberger, 2004). AID-mediated SHM 
was monitored using the sIgM+ DT40 line V AIDR, in which the IgV 
pseudogenes have been ablated (gift of H. Arakawa and J.-M. Buerstedde, In-
stitute for Molecular Radiobiology, Neuherberg, Germany; Arakawa et al., 
2004). IgM+ cell populations were FACS sorted and expanded for 3 wk in 
24-well plates, and the IgM phenotype was analyzed by flow cytometry. Mu-
tations were scored as described previously (Di Noia and Neuberger, 2004) 
in V sequences PCR amplified from unsorted populations after expansion. 
To analyze CSR, CH12F3-2 cells were preincubated with CFSE (Invitrogen) 
according to manufacturer’s instruction before activation with 1 ng/ml TGF-1, 
10 ng/ml recombinant murine IL-4, and 1 µg/ml functional grade puri-
fied anti–mouse CD40 (BD). For chronic Hsp90 inhibition, 17-AAG was 
added 4 h after activation and kept for 3 d. For acute Hsp90 inhibition,   
17-AAG was added to the medium for 12 h, and then the cells were washed 
twice with PBS and resuspended in fresh normal medium. IgA expression 
was monitored at day 3 after stimulation using PE-conjugated anti–mouse 
IgA antibody (eBioscience). Resting B cells from AID-deficient mice were 
purified by MACS CD43 depletion (Miltenyi Biotech) from total splenic 
lymphocytes (Patenaude et al., 2009). Cells were loaded with CFSE, and   
106 cells/well were seeded in 24-well plates with 25 µg/ml LPS (Sigma-Aldrich) 
and 50 ng/ml mouse IL-4. At different times after activation, 17-AAG was 
added and washed away 12 h later with PBS, and fresh culture medium was 
replenished. Isotype switching was analyzed 4 d after activation by flow cytom-
etry after staining with anti–IgG1-biotin (BD), followed by APC-conjugated 
antibiotin antibody (Miltenyi Biotech) and propidium iodide.
Imatinib resistance assay. K562 cells stably expressing AID-ires-GFP or 
GFP control were mixed with the parental cell line at a fixed ratio. The ratio 
MA) for mouse AID, 1:3,000 antiactin (Sigma-Aldrich), 1:1,000 anti- 
monoubiquitinated and -polyubiquitinated conjugates antibody (Enzo Life 
Sciences, Inc.) for endogenous ubiquitin, 1:1,000 mAb anti-CHIP (Sigma-
Aldrich), 1:2,000 anti-UNG2 (specific for nuclear isoform; Abcam), 1:2,500 
anti-MSH6 (Bethyl Laboratories, Inc.), 1:5,000 anti-PCNA (PC-10; Abcam), 
1:1,000 anti–DNA-PK (Santa Cruz Biotechnology, Inc.), 1:1,000 anti-Lck 
(gift  of A. Veillette,  Institut  de  Recherches  Cliniques  de  Montréal),  and 
1:1,000 anti–c-abl (EMD). Secondary antibodies were used according to the 
species of the primary antibody: 1:5,000 goat anti–mouse-HRP and 1:10,000 
anti–rabbit-HRP (Dako) and 1:5,000 goat anti–rat-HRP (Millipore).
Mice and cell lines. HeLa cells stably expressing AID-GFP were generated 
by transfecting with pEF-AID-EGFP and selecting with 2.5 µg/ml puromy-
cin. Ramos cell lines stably expressing GFP, AID-GFP, and AID-Flag/HA 
have been described previously (Patenaude et al., 2009). Ramos cells express-
ing Myc-CHIP were generated by transfecting with pcDNA3.1 Myc-CHIP 
(a gift of L. Petrucelli, Mayo Clinic, Jacksonville, FL) and selecting with G418. 
Subclones  from  three  independent  Myc-CHIP  Ramos  transfectants  and 
controls were obtained by single cell deposition. Populations of Ramos cells 
stably expressing chimeras AID-A2 #1 or #2 and DT40 cells stably express-
ing GFP or AID-GFP as well as the CML cell line K562 (a gift of T. Moroy) 
stably expressing AID-ires-GFP or GFP control were obtained by retroviral 
delivery of these genes cloned in pMXs vectors.  The supernatant of HEK293T 
cells cotransfected with pMX and vectors expressing MLV Gag-Pol and   
VSV-G envelope (3:1:1 ratio) was used to infect 106 cells by spin-infection at 
600 g for 1 h at room temperature in the presence of 16 µg/ml polybrene and   
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of GFP+ to GFP cells was measured by flow cytometry every 2 d for popu-
lations under the different treatments indicated in the figure (2 µM DMSO, 
2 µM imatinib, and 0.1 µM 17-AAG). GFP+ cells were FACS sorted at the 
end of the experiments for the relevant conditions. Relative imatinib resis-
tance of these populations was determined using Celltiter 96 Aqueous non-
radioactive cell proliferation assay (Promega) according to manufacturer’s 
instruction. For mutation analysis of the BCR-ABL1 gene, single GFP+ CML 
cells expressing AID or not were sorted at the end of the treatments and ex-
panded to obtain a clone in 96-well plates. RNA was extracted with  TRIZOL 
(Invitrogen), and cDNA synthesis was performed using M-MULV first strand 
cDNA synthesis kit (New England Biolabs, Inc.). A 1540-bp fragment of the 
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Polymerase (EMD). PCR products were purified and directly sequenced   
using an ABL1-specific primer.
Statistical analysis. The unpaired two-tailed Student’s t test was used.
Online supplemental material. Fig. S1 shows the expression levels of 
transfected AID in Ramos B cells and endogenous Hsp90 and CHIP in   
B cells and B cell lines as well as the interaction of Hsp90 with oligomerization-
deficient and phospho-null AID mutants and with GFP-AID. Fig. S2 shows 
that inhibiting or activating PKA in Ramos cells has no effect on the decay 
of AID-GFP after Hsp90 inhibition. Fig. S3 shows that inhibition of Hsp90 
does not lead to relocalization of AID from the cytoplasm to the nucleus.   
Fig. S4 shows that Hsp90 prevents proteasomal degradation of AID-GFP   
in DT40 chicken B cells and in HeLa cells and the dose–response curves for 
AID-GFP levels in Ramos cells treated with GA. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20101321/DC1.
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